SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA Declines to Approve Capricor Duchenne Treatment Over Unreliable Trial Data

The FDA declined to approve Capricor's Duchenne treatment, citing unreliable trial data. Capricor shares slumped.

CAPR

Related stories